{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"88.0","value":"3.78"},{"groupId":"OG001","spread":"87.5","value":"2.71"},{"groupId":"OG002","spread":"43.6","value":"3.20"},{"groupId":"OG003","spread":"4.5","value":"1.66"},{"groupId":"OG004","spread":"71.1","value":"5.01"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"}],"units":"Participants"}],"description":"T1/2: The apparent first-order elimination half-life","dispersionType":"Standard Deviation","groups":[{"description":"Cohort 1: Participants were administered E6201 240 mg/m\\^2 IV over 2 hours once weekly, on Days 1, 8, 15, and 22, repeated every 28 days (= 1 cycle) until progression of disease, toxicity or other reason for discontinuation of study drug, and followed for up to 6 months after the last dose.","id":"OG000","title":"E6201 240 mg/m^2 Weekly"},{"description":"Cohort 2: Participants were administered E6201 320 mg/m\\^2 IV over 2 hours once weekly, on Days 1, 8, 15, and 22, repeated every 28 days (= 1 cycle) until progression of disease, toxicity or other reason for discontinuation of study drug, and followed for up to 6 months after the last dose.","id":"OG001","title":"E6201 320 mg/m^2 Weekly"},{"description":"Cohort 3: Participants were administered E6201 160 mg/m\\^2 IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22 and 25, repeated every 28 days (= 1 cycle) until progression of disease, toxicity or other reason for discontinuation of study drug, and followed for up to 6 months after the last dose.","id":"OG002","title":"E6201 160 mg/m^2 Twice Weekly"},{"description":"Cohort 4: Participants were administered E6201 240 mg/m\\^2 IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22 and 25, repeated every 28 days (= 1 cycle) until progression of disease, toxicity or other reason for discontinuation of study drug, and followed for up to 6 months after the last dose.","id":"OG003","title":"E6201 240 mg/m^2 Twice Weekly"},{"description":"Cohort 5: Participants were administered E6201 320 mg/m\\^2 IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22 and 25, repeated every 28 days (= 1 cycle) until progression of disease, toxicity or other reason for discontinuation of study drug, and followed for up to 6 months after the last dose.","id":"OG004","title":"E6201 320 mg/m^2 Twice Weekly"}],"paramType":"MEAN","populationDescription":"All subjects in the FAS who completed at least 1 pharmacokinetic (PK) assessment.","reportingStatus":"POSTED","timeFrame":"Assessed at Cycle 1 Days 1 and 15, Cycle 2 Day 1, pre-dose, 5 minutes following the end of the 2-hour infusion, 2, 4, 8 and 24 hours post-infusion. Summary PK parameters for Cycle 1 Day 1 reported.","title":"Pharmacokinetic Profile of E6201 in Plasma: T1/2","type":"SECONDARY","unitOfMeasure":"h"}